- Home
- BGT vs ACIU Comparison
BGT vs ACIU Comparison
Compare BGT & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BGT | ACIU |
|---|---|---|
| Founded | 2004 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 320.3M | 213.3M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | BGT | ACIU |
|---|---|---|
| Price | $11.36 | $3.10 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 107.2K | ★ 1.4M |
| Earning Date | 01-01-0001 | 11-04-2025 |
| Dividend Yield | ★ 10.77% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,482,957.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $644.42 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.89 | $1.43 |
| 52 Week High | $13.42 | $4.00 |
Technical Indicators
Market Signals| Indicator | BGT | ACIU |
|---|---|---|
| Relative Strength Index (RSI) | 52.89 | 53.05 |
| Support Level | $11.21 | $2.87 |
| Resistance Level | $11.41 | $3.21 |
| Average True Range (ATR) | 0.09 | 0.29 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 94.29 | 46.83 |
Price Performance
Historical ComparisonAbout BGT BlackRock Floating Rate Income Trust
Blackrock Floating Rate Income Trust is a closed-end management investment company. Its investment objective is to provide a high level of current income. The company's secondary investment objective is to seek the preservation of capital. The Trust seeks to achieve its investment objectives by investing mainly, under normal conditions, at least 80% of its assets in floating and variable rate instruments of U.S. and non-U.S. issuers, including a substantial portion of its assets in floating and variable rate securities including senior secured floating rate loans made to corporate and other business entities.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.